Connor Clark & Lunn Investment Management Ltd. Has $230,000 Holdings in Boston Scientific Corporation $BSX

Connor Clark & Lunn Investment Management Ltd. trimmed its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 98.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,145 shares of the medical equipment provider’s stock after selling 105,935 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Boston Scientific were worth $230,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Sound Income Strategies LLC raised its position in shares of Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares in the last quarter. 1248 Management LLC bought a new position in Boston Scientific during the 1st quarter worth $26,000. Y.D. More Investments Ltd acquired a new position in Boston Scientific in the 1st quarter valued at $27,000. Princeton Global Asset Management LLC bought a new stake in shares of Boston Scientific during the 2nd quarter valued at $32,000. Finally, Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Boston Scientific by 72.9% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 344 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 145 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on BSX. Morgan Stanley boosted their price target on Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. The Goldman Sachs Group reaffirmed a “buy” rating and set a $124.00 price target on shares of Boston Scientific in a report on Wednesday, October 22nd. Wells Fargo & Company increased their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. BTIG Research restated a “buy” rating and set a $132.00 price objective on shares of Boston Scientific in a research report on Friday. Finally, UBS Group raised their target price on Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $123.77.

Boston Scientific Price Performance

Shares of BSX opened at $96.77 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The stock has a market cap of $143.46 billion, a PE ratio of 51.75, a PEG ratio of 2.02 and a beta of 0.58. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50. The business has a 50-day simple moving average of $98.97 and a two-hundred day simple moving average of $102.38.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,739,678.74. The trade was a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 175,782 shares of company stock worth $17,742,314 over the last three months. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.